DexCom Inc (DXCM)vsLivaNova PLC (LIVN)
DXCM
DexCom Inc
$75.14
+0.39%
HEALTHCARE · Cap: $29.58B
LIVN
LivaNova PLC
$81.43
-0.80%
HEALTHCARE · Cap: $4.43B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 236% more annual revenue ($4.82B vs $1.43B). DXCM leads profitability with a 19.3% profit margin vs 7.5%. LIVN appears more attractively valued with a PEG of 0.93. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
LIVN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.6%
Fair Value
$656.95
Current Price
$75.14
$581.81 discount
Margin of Safety
+5.6%
Fair Value
$70.39
Current Price
$81.43
$11.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.8x book value
7.5% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : LIVN
The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : LIVN
The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 41.2x leaves little room for execution misses.
Key Dynamics to Monitor
DXCM profiles as a mature stock while LIVN is a value play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 52/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?